FDA okays ViiV's Apretude as first injectable for HIV PrEP

GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrE

Gilead’s Descovy gets FDA panel OK for PrEP, but not for wom...

FDA reviewer backs Gilead’s Descovy for PrEP, but not in wom...

Gilead files Truvada follow-up Descovy for PrEP

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six m